Zinier raises $22 million from Accel, Qualcomm, others to automate field service management
Excerpt: (Mar 5, 2019) Zinier, a startup that wants to bring automation to the field service management (FSM) realm, has raised $22 million in a series B round of funding led by Accel, with participation from Qualcomm Ventures, Nokia-backed venture capital (VC) firm NGP Capital, Peter Thiel’s Founders Fund, and France’s Newfund.
Today, Zinier counts roughly 70 employees globally, around half of whom are based out of Bengaluru, India, with some 15 based in San Francisco, 10 in Mexico City, and 10 in Singapore. In addition to its series B round of funding, Zinier also today revealed that it had raised $8 million in an Accel-led series A round last year. With another $22 million in the bank, the company plans to target industries beyond telecom and energy, as well as new regions.
Read the full coverage here
InstaReM nabs US$41m in Series C funding, final close led by Vertex Growth Fund
Excerpt: (Mar 19, 2019) Digital payments company InstaReM has closed a Series C funding round at US$41 million in Singapore. The final close of US$20 million was led by Singapore-based Vertex Growth Fund and supported by new investor, Atinum Investment from South Korea.
The InstaReM investment marks Vertex Growth Fund’s first investment in South-east Asia and will see its managing director James Lee joining InstaReM’s board.
Read the full story here
Lucence Diagnostics to develop AI tools for treating liver cancer
Exercept (Mar 19, 2019) Lucence Diagnostics, a genomic medicine company focused on personalizing cancer care, has announced a new project to develop AI algorithms for improving diagnosis and treatment of liver cancer.
The goal is to combine the imaging and molecular data from liver cancer patients into smarter software tools that help physicians make better treatment decisions.
Lucence will be working with Olivier Gevaert, PhD, Assistant Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science at the Stanford University School of Medicine. Having developed LiquidHALLMARK®, the world’s first liquid biopsy nextgeneration sequencing test that analyzes the DNA of cancer-causing mutations and viruses, Lucence will contribute its genomics expertise and proprietary sequencing technology to this project.
This project will evaluate a dataset of over 5,000 patients to identify image changes and patterns that are linked to diagnostic and treatment outcomes in liver cancer.
Get the story here.
|Incubate with us to gain access to wide global community connections and deep industry support. Learn more or apply now at https://www.block71sf.com/startup-support/ or drop us a hello at email@example.com|